Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Insulin/IGF-1 Drives PERIOD Synthesis to Entrain Circadian Rhythms with Feeding Time.

Crosby P, Hamnett R, Putker M, Hoyle NP, Reed M, Karam CJ, Maywood ES, Stangherlin A, Chesham JE, Hayter EA, Rosenbrier-Ribeiro L, Newham P, Clevers H, Bechtold DA, O'Neill JS.

Cell. 2019 May 2;177(4):896-909.e20. doi: 10.1016/j.cell.2019.02.017. Epub 2019 Apr 25.

2.

Optimizing drug discovery by Investigative Toxicology: Current and future trends.

Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T, Newham P, Oinonen T, Pognan F, Roth A, Valentin JP, Van Goethem F, Weaver RJ, Birk B, Boyer S, Caloni F, Chen AE, Corvi R, Cronin MTD, Daneshian M, Ewart LC, Fitzgerald RE, Hamilton GA, Hartung T, Kangas JD, Kramer NI, Leist M, Marx U, Polak S, Rovida C, Testai E, Van der Water B, Vulto P, Steger-Hartmann T.

ALTEX. 2019;36(2):289-313. doi: 10.14573/altex.1808181. Epub 2018 Dec 20.

3.

Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.

Ewart L, Dehne EM, Fabre K, Gibbs S, Hickman J, Hornberg E, Ingelman-Sundberg M, Jang KJ, Jones DR, Lauschke VM, Marx U, Mettetal JT, Pointon A, Williams D, Zimmermann WH, Newham P.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:65-82. doi: 10.1146/annurev-pharmtox-010617-052722. Epub 2017 Oct 13. Review.

PMID:
29029591
4.

The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator.

Grant C, Ewart L, Muthas D, Deavall D, Smith SA, Clack G, Newham P.

Toxicol Appl Pharmacol. 2016 Apr 1;296:10-8. doi: 10.1016/j.taap.2016.02.007. Epub 2016 Feb 11.

PMID:
26876616
5.

Quantification of Low-Level Drug Effects Using Real-Time, in vitro Measurement of Oxygen Consumption Rate.

Neal A, Rountree AM, Philips CW, Kavanagh TJ, Williams DP, Newham P, Khalil G, Cook DL, Sweet IR.

Toxicol Sci. 2015 Dec;148(2):594-602. doi: 10.1093/toxsci/kfv208. Epub 2015 Sep 22.

6.

Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.

Newham P, Ross D, Ceuppens P, Das S, Yates JW, Betts C, Reens J, Randall KJ, Knight R, McKay JS.

Inflamm Res. 2014 Feb;63(2):149-60. doi: 10.1007/s00011-013-0683-3. Epub 2013 Nov 17.

PMID:
24240228
7.

Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα.

Abbott WM, Snow M, Eckersley S, Renshaw J, Davies G, Norman RA, Ceuppens P, Slootstra J, Benschop JJ, Hamuro Y, Lee JE, Newham P.

Biosci Rep. 2013 Aug 23;33(4). pii: e00060. doi: 10.1042/BSR20130044.

8.

Dual regulation of metalloproteinase expression in chondrocytes by Wnt-1-inducible signaling pathway protein 3/CCN6.

Baker N, Sharpe P, Culley K, Otero M, Bevan D, Newham P, Barker W, Clements KM, Langham CJ, Goldring MB, Gavrilović J.

Arthritis Rheum. 2012 Jul;64(7):2289-99. doi: 10.1002/art.34411.

9.

Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration.

McGinn OJ, English WR, Roberts S, Ager A, Newham P, Murphy G.

Cell Biol Int. 2011 Oct;35(10):1043-53. doi: 10.1042/CBI20100885.

PMID:
21332445
10.

Matrix metalloproteinase 17 is necessary for cartilage aggrecan degradation in an inflammatory environment.

Clements KM, Flannelly JK, Tart J, Brockbank SM, Wardale J, Freeth J, Parker AE, Newham P.

Ann Rheum Dis. 2011 Apr;70(4):683-9. doi: 10.1136/ard.2010.130757. Epub 2011 Jan 7.

PMID:
21216815
11.

Novel inhibitors of the alphavbeta3 integrin--lead identification strategy.

Elliot D, Henshaw E, MacFaul PA, Morley AD, Newham P, Oldham K, Page K, Rankine N, Sharpe P, Ting A, Wood CM.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4832-5. doi: 10.1016/j.bmcl.2009.06.041. Epub 2009 Jun 13.

PMID:
19574045
12.

Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1.

Blom AB, Brockbank SM, van Lent PL, van Beuningen HM, Geurts J, Takahashi N, van der Kraan PM, van de Loo FA, Schreurs BW, Clements K, Newham P, van den Berg WB.

Arthritis Rheum. 2009 Feb;60(2):501-12. doi: 10.1002/art.24247.

13.

Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized.

Hunter DJ, Gerstenfeld L, Bishop G, Davis AD, Mason ZD, Einhorn TA, Maciewicz RA, Newham P, Foster M, Jackson S, Morgan EF.

Arthritis Res Ther. 2009;11(1):R11. doi: 10.1186/ar2601. Epub 2009 Jan 26.

14.

The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13.

Jones SW, Watkins G, Le Good N, Roberts S, Murphy CL, Brockbank SM, Needham MR, Read SJ, Newham P.

Osteoarthritis Cartilage. 2009 Apr;17(4):464-72. doi: 10.1016/j.joca.2008.09.012. Epub 2008 Oct 11.

15.

Gene expression profiles at different stages of collagen-induced arthritis.

Booth G, Newham P, Barlow R, Raines S, Zheng B, Han S.

Autoimmunity. 2008 Nov;41(7):512-21. doi: 10.1080/08916930802095210.

PMID:
18608173
16.

Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology.

Jones SW, Brockbank SM, Clements KM, Le Good N, Campbell D, Read SJ, Needham MR, Newham P.

Osteoarthritis Cartilage. 2009 Jan;17(1):124-31. doi: 10.1016/j.joca.2008.05.001. Epub 2008 Jun 17.

17.

Transcriptional profiling of the LPS induced NF-kappaB response in macrophages.

Sharif O, Bolshakov VN, Raines S, Newham P, Perkins ND.

BMC Immunol. 2007 Jan 12;8:1.

18.

The orphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover.

Jones SW, Brockbank SM, Mobbs ML, Le Good NJ, Soma-Haddrick S, Heuze AJ, Langham CJ, Timms D, Newham P, Needham MR.

Osteoarthritis Cartilage. 2006 Jun;14(6):597-608. Epub 2006 May 2.

19.

Characterisation of cell-penetrating peptide-mediated peptide delivery.

Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SM, Newham P, Lindsay MA.

Br J Pharmacol. 2005 Aug;145(8):1093-102.

20.

A specific alpha5beta1-integrin conformation promotes directional integrin translocation and fibronectin matrix formation.

Clark K, Pankov R, Travis MA, Askari JA, Mould AP, Craig SE, Newham P, Yamada KM, Humphries MJ.

J Cell Sci. 2005 Jan 15;118(Pt 2):291-300. Epub 2004 Dec 22.

21.

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.

Baxter A, Brough S, Cooper A, Floettmann E, Foster S, Harding C, Kettle J, McInally T, Martin C, Mobbs M, Needham M, Newham P, Paine S, St-Gallay S, Salter S, Unitt J, Xue Y.

Bioorg Med Chem Lett. 2004 Jun 7;14(11):2817-22.

PMID:
15125939
22.

Expression and purification of biologically active IGF-binding proteins using the LCR/Mel expression system.

Bagnall W, Sharpe PM, Newham P, Tart J, Mott RA, Torr VR, Forder RA, Needham MR.

Protein Expr Purif. 2003 Jan;27(1):1-11.

PMID:
12509978
23.

A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopin.

Cosulich SC, James NH, Needham MR, Newham PP, Bundell KR, Roberts RA.

Carcinogenesis. 2000 Sep;21(9):1757-60.

PMID:
10964109
24.

Production of recombinant soluble human integrin alpha4beta1.

Clark K, Newham P, Burrows L, Askari JA, Humphries MJ.

FEBS Lett. 2000 Apr 14;471(2-3):182-6.

25.

The structure of cell-adhesion molecules.

Humphries MJ, Newham P.

Trends Cell Biol. 1998 Feb;8(2):78-83. Review.

PMID:
9695813
27.

Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity.

Newham P, Craig SE, Seddon GN, Schofield NR, Rees A, Edwards RM, Jones EY, Humphries MJ.

J Biol Chem. 1997 Aug 1;272(31):19429-40.

28.

Surface loops adjacent to the cation-binding site of the complement factor B von Willebrand factor type A module determine C3b binding specificity.

Tuckwell DS, Xu Y, Newham P, Humphries MJ, Volanakis JE.

Biochemistry. 1997 Jun 3;36(22):6605-13.

PMID:
9184140
29.

Integrin adhesion receptors: structure, function and implications for biomedicine.

Newham P, Humphries MJ.

Mol Med Today. 1996 Jul;2(7):304-13. Review.

PMID:
8796911
30.

Identification of a key structural element in VCAM-1.

Newham P, Humphries MJ.

Biochem Soc Trans. 1995 Nov;23(4):512S. No abstract available.

PMID:
8654697
31.

Mechanisms of VCAM-1 and fibronectin binding to integrin alpha 4 beta 1: implications for integrin function and rational drug design.

Humphries MJ, Sheridan J, Mould AP, Newham P.

Ciba Found Symp. 1995;189:177-91; discussion 191-9. Review.

PMID:
7587632
32.

Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin.

Clements JM, Newham P, Shepherd M, Gilbert R, Dudgeon TJ, Needham LA, Edwards RM, Berry L, Brass A, Humphries MJ.

J Cell Sci. 1994 Aug;107 ( Pt 8):2127-35.

33.

Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin alpha 4 beta 1.

Makarem R, Newham P, Askari JA, Green LJ, Clements J, Edwards M, Humphries MJ, Mould AP.

J Biol Chem. 1994 Feb 11;269(6):4005-11.

34.

Differential expression of e-cadherin in normal, metaplastic and dysplastic esophageal mucosa - a putative biomarker.

Jankowski J, Newham P, Kandemir O, Hirano S, Takeichi M, Pignatelli M.

Int J Oncol. 1994 Feb;4(2):441-8.

PMID:
21566944
35.

Mechanism of integrin alpha 4 beta 1-VCAM-1 interaction.

Newham P, Tuckwell DS, Brass A, Humphries MJ.

Biochem Soc Trans. 1993 Nov;21(4):339S. No abstract available.

PMID:
7510643

Supplemental Content

Loading ...
Support Center